E2F2 and breast carcinoma: Inhibition of E2F2 could reduce the proportion of CD24-/CD44+ cells and the expression levels of SOX2 and OCT4, thus inhibiting the self-renewal, proliferation and invasion ability of BCSCs and inhibiting the growth of breast cancer tumors (23).